Dr. Rekdal is co-founder of Lytix Biopharma and has extensive research background within tumor immunology, oncolytic peptides and their abilities to induce potent tumor specific immune responses. Dr. Rekdal commenced his PhD on cytokines and tumor immunology in 1996, and his postdoctoral work, focusing on oncolytic peptides and their abilities to induce potent tumor specific immune responses, forms the basis of Lytix Biopharma’s oncolytic peptide platform.

Dr. Rekdal is leading the collaboration with several distinguished researchers and institutions to further explore the unique ability of oncolytic peptides to reprogram non-inflamed or suppressive tumor microenvironment in experimental models and in cancer patients.

Mr. Breistein has long experience from PwC as an auditor and consultant working with public and private companies across multiple industry sectors. Before joining Lytix Biopharma he was in PwC’s capital markets group advising clients in capital market transactions, financing and listing processes.

Mr. Breistein is a state authorized public accountant, and he holds a master in applied economics and finance from Copenhagen Business School and a master in professional accountancy from BI Norwegian School of Management.

Baldur Sveinbjørnsson achieved a Dr. Philos degree at the Medical Faculty of University of Tromsø in 1998, with a focus on mechanisms and mediators behind  immunomodulation of experimental tumors. Since then, Dr. Sveinbjørnsson has gained a broad experience of preclinical oncology at University of Tromsø and Karolinska Institutet Stockholm.

Dr. Sveinbjørnsson has been involved in the research activities of Lytix Biopharma since the beginning and has the last years led the company research activities as Director Scientific Research.

Dr. Stensrud has more than 20 years expertise in research, development, clinical trials, manufacturing and distribution of medicinal products and medical devices as well as extensive leadership experience and former experience in developing a Biotech company.

Dr. Stensrud has held different positions within R&D, QA and commercial manufacture/supply at GE Healthcare and Photocure. Prior to joining Lytix, Dr. Stensrud was Vice President Technical Development & Operations at Photocure. Dr. Stensrud holds a degree in Pharmacy and a PhD in Pharmaceutical Technology.

Dr. Currie has over 30 years of drug development experience in both pharmaceutical and biotechnology companies, having held senior leadership roles at Dynavax, Regeneron Pharmaceuticals, Sepracor Inc., PDL Biopharma and Gilead Sciences.  Most recently, he was Chief Development Officer of Tolerion Inc. Dr. Currie has successfully led drug development programs and has held key roles in the development of 8 approved drugs.

Dr. Currie holds a PhD from Aston University in the UK.

Mr. Worsley has more than 25 years experience with business development leadership in roles of increasing impact and in executing high-valuation strategic deals in the biopharmaceutical and drug discovery/development market. Most recently Mr. Worsley served as the Vice President Strategic Business Development at Redwood Biosciences/ Catalent Pharma Services. Mr. Worsley is a seasoned life sciences executive who also served roles as the CBO at Sutro Biopharma, Sr. Vice President Business Development at IndiMolecular and Vice President of Business Development at Peregrine Pharmaceutical (dba Avid Pharma Services) amongst other roles in his career. 

As a business development executive, Mr. Worsley has led negotiations of transformative and award-winning technology and product partnerships for leading therapeutics companies.

Mr. Worsley holds an MBA from the University of Washington and a BS in Econ/International Finance from the University of Utah.